PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Consensus Rating of “Hold” from Brokerages

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has earned an average rating of “Hold” from the fifteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $33.4545.

A number of research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research report on Thursday, April 30th. UBS Group lowered shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price on the stock. in a research note on Tuesday. Citigroup cut shares of PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. Finally, Truist Financial reissued a “hold” rating and issued a $25.00 price target (down from $30.00) on shares of PROCEPT BioRobotics in a research note on Thursday, July 2nd.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRCT. Caitong International Asset Management Co. Ltd raised its holdings in PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after buying an additional 1,084 shares in the last quarter. Center for Financial Planning Inc. purchased a new stake in shares of PROCEPT BioRobotics in the 4th quarter worth about $40,000. US Bancorp DE grew its position in shares of PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after buying an additional 1,079 shares during the period. Finally, Cache Advisors LLC bought a new position in shares of PROCEPT BioRobotics in the 1st quarter worth about $42,000. 89.46% of the stock is owned by hedge funds and other institutional investors.

PROCEPT BioRobotics Price Performance

Shares of PROCEPT BioRobotics stock opened at $18.62 on Friday. The company has a quick ratio of 5.51, a current ratio of 6.73 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.06 billion, a PE ratio of -10.23 and a beta of 0.87. The business has a 50 day moving average of $22.39 and a 200 day moving average of $25.19. PROCEPT BioRobotics has a 52 week low of $16.67 and a 52 week high of $51.38.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). The business had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $80.52 million. PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The business’s revenue was up 20.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.45) EPS. As a group, equities research analysts forecast that PROCEPT BioRobotics will post -1.53 earnings per share for the current year.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff in the pending class action. The notices are procedural and do not represent a court finding of wrongdoing. Deadline Alert: Procept BioRobotics Corporation Shareholders
• Negative Sentiment: The core allegations involve repeated underperformance in unit and handpiece sales, late-quarter bulk discounts, excess customer inventory, and sales being pulled forward. Plaintiffs allege these practices may have inflated recurring-revenue metrics and that the risks were not adequately disclosed. PROCEPT Faces Securities Class Action Amid Sales Pull-In Concerns
• Negative Sentiment: The unusually high volume of nearly identical law-firm announcements increases the visibility of the litigation and could weigh on the stock through potential legal costs, reputational damage, and uncertainty regarding the sustainability of demand and future revenue growth. PROCEPT Securities Fraud Class Action and Inventory Issues
• Negative Sentiment: UBS reportedly lowered its rating on PRCT to “Neutral,” adding to the cautious backdrop surrounding the company and its sales outlook. PROCEPT Rating Lowered to Neutral at UBS

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.